Drug
Emtricitabine clinical trials
Also written Emtriva and FTC.
Counted the way a researcher would: Emtricitabine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Emtricitabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Emtricitabine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 Jul 2003 · EMTRIVA · NDA 021500 (FDA, Drugs@FDA)
- European Union
- 24 Oct 2003 · Emtriva · EMEA/H/C/000533 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
175 studies that test it; most in 2015 (20)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 6 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 9 |
| 2014 | 9 |
| 2015 | 20 |
| 2016 | 12 |
| 2017 | 10 |
| 2018 | 12 |
| 2019 | 9 |
| 2020 | 12 |
| 2021 | 9 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 60 · Other 118
Gilead Sciences (41) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Asian-Pacific Alliance of Liver Disease, Beijing (5) · French National Agency for Research on AIDS and Viral Hepatitis (4) · Kirby Institute (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (4) · Juan A. Arnaiz (4) · University of California, San Francisco (3)
Often tested with
Tested in the same studies.
Tenofovir (81) · Tenofovir alafenamide (68) · Bictegravir (33) · Cobicistat (30) · Elvitegravir (21) · Darunavir (17) · Efavirenz (14) · Ritonavir (12)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 7 phase 3 studies under way
Emtricitabine is the comparator. A study of two new drugs counts under both.
- 3Islatravir · Merck Sharp & Dohme LLC · next primary completion Feb 2029
- 2Lamivudine · ViiV Healthcare, José Antonio Mata Marín
- 1Bictegravir · Gilead Sciences
- 1Lenacapavir · Gilead Sciences
- 1Dolutegravir · ViiV Healthcare
- 1Lepetegravir · Gilead Sciences · next primary completion Jan 2028
- 1Ulonivirine · Merck Sharp & Dohme LLC · next primary completion Feb 2029
- 1Tenofovir · José Antonio Mata Marín
Reaching primary completion within a year · 5
Studies that test Emtricitabine.
- Nov 2026Antiviral Clinical Trial for Long Covid-19Phase 2 · Icahn School of Medicine at Mount Sinai
- May 2027Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionPhase 4 · University of California, San Francisco
- Jun 2027A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsPhase 4 · Gilead Sciences
- Jun 2027REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidEPhase 4 · CAN Community Health
- Aug 2027A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Phase 2 · Gilead Sciences
Studies
Open first, then newest update. How each study uses Emtricitabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 178
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingPhase 2Gilead SciencesNCT07645287Written as B/F/TAF
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingPhase 2/3Gilead SciencesNCT07708727Written as B/F/TAF
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as E/C/F/TAF
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingPhase 4CAN Community HealthNCT07476339Written as Bictegravir, emtricitabine, and tenofovir alafenamide
- Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's DiseaseNot yet recruitingPhase 1Brigham and Women's HospitalNCT07795307Written as Emtricitabine and tenofovir disoproxil fumarate combination
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Emtricitabine (FTC)
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07678268Written as Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine
- Antiviral Clinical Trial for Long Covid-19RecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT06511063Written as tenofovir disoproxil/emtricitabine
- Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of ADRecruitingPhase 1Butler HospitalNCT04500847Written as Emtriva Capsule
- The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT06375304Written as B/F/TAF
- Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingPhase 3MRC/UVRI and LSHTM Uganda Research UnitNCT06133686Written as Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionActive, not recruitingPhase 3Gilead SciencesNCT04994509Written as F/TAF
- Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 InfectionTerminatedPhase 3Gilead SciencesNCT02842086Written as F/TAF
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVActive, not recruitingPhase 1Gilead SciencesNCT07055451Written as B/F/TAF
- A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)CompletedPhase 1Merck Sharp & Dohme LLCNCT07532304Written as Bictegravir/emtricitabine/tenofovir alafenamide
- IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration ProjectCompletedPhase 4Rutgers, The State University of New JerseyNCT03058835Written as tenofovir disoproxil and emtricitabine
- Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore StudyActive, not recruitingPhase 1National University Hospital, SingaporeNCT07210528Written as Emtricitabine (FTC)
- Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionActive, not recruitingPhase 4University of California, San FranciscoNCT02656511Written as Emtricitabine/Tenofovir
- Biktarvy in Treatment-Naïve Late Presenters With HIV-1 InfectionCompletedPhase 4Peking Union Medical College HospitalNCT04296695Written as B/F/TAF
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1Active, not recruitingPhase 3Gilead SciencesNCT06630286Written as B/F/TAF
See all 178 studies that test Emtricitabine →
Given beside what is tested · 43 — Emtricitabine is usual care or a partner of the new treatment
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)RecruitingPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT07711223Written as ACC017+FTC/TAF
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTRecruitingPhase 3Africa Health Research InstituteNCT06250504Written as tenofovir disoproxil and emtricitabine
- Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult ParticipantsCompletedPhase 1Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT06278389Written as Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
- Phase Ib/IIa Clinical Study of ACC017 TabletsCompletedPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT06719310Written as ACC017+FTC/TAF
- Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)CompletedPhase 3French National Agency for Research on AIDS and Viral HepatitisNCT00302822Written as emtricitabine/tenofovir
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenCompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT02720094Written as TDF/FTC tablets
- Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingPhase 2Gilead SciencesNCT05052996Written as B/F/TAF
- Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenActive, not recruitingPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03164564Written as Oral TDF/FTC
- Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant PatientsCompletedPhase 4Fundacion Clinic per a la Recerca BiomédicaNCT03360682Written as Emtricitabine 200 MG
- DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young MenCompletedPhase 4Public Health Foundation Enterprises, Inc.NCT03771638Written as Emtricitabine / Tenofovir Disoproxil Oral Tablet
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenCompletedPhase 2/3Gilead SciencesNCT02285114Written as F/TAF
- Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent MalesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04692077Written as Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
- Study of Novel Antiretrovirals in Participants With HIV-1CompletedPhase 1Gilead SciencesNCT05585307Written as B/F/TAF
- A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of CareCompletedPhase 3Janssen Scientific Affairs, LLCNCT03227861Written as DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent FemalesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04824131Written as Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01400412Written as Emtricitabine
- A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsCompletedPhase 2Janssen Sciences Ireland UCNCT00799864Written as Emtricitabine
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedPhase 1/2SEARCH Research FoundationNCT02475915Written as Emtricitabine
- Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT02607930Written as B/F/TAF
- Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00051831Written as Emtricitabine
Showing 20 of 43.
As the comparator · 37 — what is tested is compared with Emtricitabine
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07266831Written as BIC/FTC/TAF
- Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsRecruitingPhase 2Gilead SciencesNCT07841990Written as B/F/TAF
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)RecruitingPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT07711223Written as ACC017+FTC/TAF
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityRecruitingPhase 3José Antonio Mata MarínNCT07075146Written as BIC/FTC/TAF
- Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07031063Written as Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyActive, not recruitingPhase 3Gilead SciencesNCT06333808Written as B/F/TAF
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingPhase 3ViiV HealthcareNCT05979311Written as Emtricitabine
- DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05705349Written as BIC/FTC/TAF
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233879Written as BIC/FTC/TAF
- Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedActive, not recruitingPhase 2/3Gilead SciencesNCT06544733Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedTerminatedPhase 2/3Gilead SciencesNCT06613685Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT04223791Written as BIC/FTC/TAF
- Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]CompletedPhase 2Merck Sharp & Dohme LLCNCT04564547Written as BIC/FTC/TAF
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05630755Written as BIC/FTC/TAF
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06891066Written as BIC/FTC/TAF
- Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineCompletedPhase 3Juan A. ArnaizNCT02284035Written as EFV/TDF/FTC
- Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir AlafenamideCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT04636437Written as Tenofovir alafenamide/emtricitabine
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight GainCompletedPhase 4Janssen Scientific Affairs, LLCNCT04442737Written as TAF/FTC FDC
- The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)CompletedPhase 2HIV Prevention Trials NetworkNCT01327651Written as Daily dosing
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedPhase 3ViiV HealthcareNCT01910402Written as Tenofovir/emtricitabine FDC
Showing 20 of 37.
Codes
What other systems call Emtricitabine · ClinicalTrials.gg INT006529
- MeSH (NLM) D000068679EmtricitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G70B4ETF4SEMTRICITABINEConfirmed FDA, NLM, Wikidata
- RxNorm 276237Confirmed FDA, Wikidata
- Wikidata Q422604emtricitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47509EmtricitabineOne source FDA
- DrugBank DB00879One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068679 | Emtricitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G70B4ETF4S | EMTRICITABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 276237 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422604 | emtricitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47509 | Emtricitabine | One source FDA |
| DrugBank | DB00879 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.